On Mar. 9, 2022, Pfizer announced today that it has initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of ProteaseInhibition forCOVID-19 in Pediatric Patients), to evaluate the safety, pharmacokinetics, and efficacy of Pfizerﾒs PAXLOVIDﾙ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) in non-hospitalized, symptomatic, pediatric participants with a confirmed diagnosis of COVID-19 who are at risk of progression to severe disease.